STAGE III RENAL PELVIS AND URETER CANCER AJCC V8
Clinical trials for STAGE III RENAL PELVIS AND URETER CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE III RENAL PELVIS AND URETER CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE III RENAL PELVIS AND URETER CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Two-Drug maintenance strategy aims to stall advanced bladder cancer
Disease control OngoingThis phase III trial tests whether adding cabozantinib to avelumab (an immunotherapy) helps keep metastatic urothelial cancer from growing after initial chemotherapy. About 654 patients will receive either the combination or avelumab alone as maintenance therapy. The goal is to s…
Matched conditions: STAGE III RENAL PELVIS AND URETER CANCER AJCC V8
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug cocktail shows promise for Hard-to-Treat urinary cancers
Disease control OngoingThis early-phase study tests a combination of two or three drugs (cabozantinib, nivolumab, and sometimes ipilimumab) in people with advanced genitourinary cancers that have spread. The main goals are to find the safest doses and understand side effects. About 152 adults with vari…
Matched conditions: STAGE III RENAL PELVIS AND URETER CANCER AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC